MiRNA research—The potential for understanding the multiple facets of anorexia nervosa

• Published in: The International journal of eating disorders Vol. 57; no. 7; pp. 1489 - 1494
• Main Authors: Voelz, Clara, Trinh, Stefanie, Käver, Larissa, Tran, Mai‐Tam, Beyer, Cordian, Seitz, Jochen
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.07.2024; Wiley Subscription Services, Inc
• Subjects: Anorexia; anorexia nervosa (AN); Anorexia Nervosa - genetics; Anorexia Nervosa - therapy; Biomarkers; depression; Depression - genetics; eating disorder; gene transcription regulation; Humans; Mental disorders; Metabolism; metabo‐psychiatric disorder; microRNA (miRNA); MicroRNAs; MicroRNAs - genetics; obesity; Obesity - genetics; eating disorder; gene transcription regulation; microRNA (miRNA); anorexia nervosa (AN); metabo‐psychiatric disorder; depression; obesity
• ISSN: 0276-3478; 1098-108X; 1098-108X
• DOI: 10.1002/eat.24204

Anorexia nervosa (AN) has a multifaceted and complex pathology, yet major gaps remain in our understanding of factors involved in AN pathology. MicroRNAs (miRNAs) play a regulatory role in translating genes into proteins and help understand and treat diseases. An extensive literature review on miRNAs with AN and comorbidities has uncovered a significant lack in miRNA research. To demonstrate the importance of understanding miRNA deregulation, we surveyed the literature on depression and obesity providing examples of relevant miRNAs. For AN, no miRNA sequencing or array studies have been found, unlike other psychiatric disorders. For depression and obesity, screenings and mechanistic studies were conducted, leading to clinical studies to improve understanding of their regulatory influences. MiRNAs are promising targets for studying AN due to their role as signaling molecules, involvement in psychiatric‐metabolic axes, and potential as biomarkers. These characteristics offer valuable insights into the disease's etiology and potential new treatment options. The first miRNA‐based treatment for rare metabolic disorders has been approved by the FDA and it is expected that these advancements will increase in the next decade. MiRNA research in AN is essential to examine its role in the development, manifestation, and progression of the disease. Public Significance The current understanding of the development and treatment of AN is insufficient. miRNAs are short regulatory sequences that influence the translation of genes into proteins. They are the subject of research in various diseases, including both metabolic and psychiatric disorders. Studying miRNAs in AN may elucidate their causal and regulatory role, uncover potential biomarkers, and allow for future targeted treatments.